Hanall Biopharma Cash Flow Reinvestment Rate
Hanall Biopharma cash flow reinvestment rate. Hanall Biopharma (009420) has a Cash Flow Reinvestment Rate of 0.45x as of September 2025, reinvesting ₩3.27 Billion (capex ₩3.27 Billion ) from operating cash flow of ₩7.34 Billion. See Hanall Biopharma financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Hanall Biopharma (2011–2024)
Cash flow reinvestment rate of Hanall Biopharma from 2011 to 2024. Historical reinvestment intensity for Hanall Biopharma across 10 annual periods. Explore Hanall Biopharma (009420) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Hanall Biopharma Cash Flow Reinvestment Rate by Year (2011–2024)
Hanall Biopharma cash flow reinvestment rate by year from 2011 to 2024. Year-by-year capital reinvestment analysis for Hanall Biopharma. For the full cash flow conversion analysis, see Hanall Biopharma (009420) cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.80x | ₩26.19 Billion | ₩9.36 Billion | ₩23.07 Billion | ▲ +293.4% |
| 2023 | 0.71x | ₩21.08 Billion | ₩29.64 Billion | ₩9.20 Billion | ▲ +211.1% |
| 2022 | 0.23x | ₩5.76 Billion | ₩25.20 Billion | ₩2.83 Billion | ▼ -99.1% |
| 2021 | 25.62x | ₩21.52 Billion | ₩839.87 Million | ₩4.61 Billion | ▲ +211.9% |
| 2020 | 8.21x | ₩7.63 Billion | ₩929.29 Million | ₩2.56 Billion | ▲ +452.7% |
| 2019 | 1.49x | ₩30.45 Billion | ₩20.49 Billion | ₩2.12 Billion | ▲ +533.8% |
| 2017 | 0.23x | ₩9.88 Billion | ₩42.14 Billion | ₩1.73 Billion | ▼ -93.8% |
| 2016 | 3.76x | ₩14.84 Billion | ₩3.95 Billion | ₩4.03 Billion | ▲ +277.6% |
| 2012 | 0.99x | ₩2.18 Billion | ₩2.20 Billion | ₩2.18 Billion | ▲ +1627.8% |
| 2011 | 0.06x | ₩426.70 Million | ₩7.41 Billion | ₩426.70 Million | — |